<DOC>
	<DOC>NCT02494999</DOC>
	<brief_summary>In order to evaluate immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine produced by Beijing Minhai Biotechnology Co., Ltd., a randomized, double-blind, parallel-controlled phase III clinical trial is planned to conduct in healthy infants aged 3-6 months in China.</brief_summary>
	<brief_title>A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants</brief_title>
	<detailed_description>There will be two arms. 900 healthy infants aged 3-6 months will be randomly assigned (1:1) to receive an experimental vaccine or a comparator vaccine in Month 0,1 and 2 (primary vaccination). All of them will receive a fourth dose as booster vaccination in Month 9.</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Aged from 3 to 6 months old on the day of inclusion Subjects' legal guardians are able to understand and sign the informed consent Subjects' legal guardians can and will comply with the requirements of the protocol Subjects with temperature &lt;=37.0°C on axillary setting Preterm infants or low birth weight infants Any administration history of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine A medical history of cultureconfirmed invasive disease caused by Streptococcus pneumonia Subject who has allergic history or serious adverse reaction history after vaccination such as allergies, hives, difficulty in breathing, angioedema or abdominal pain Subject with congenital malformation, developmental disorder, genetic defects or severe malnutrition Subject with epilepsy, a history of seizures or convulsions, or a family history of mental illness Known or suspected immune deficiency or immune suppression Diagnosed coagulation abnormalities (such as clotting factor deficiency, coagulation disorders, platelet disorder) or significant bruising or blood clotting disorder Had immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (not including allergic rhinitis corticosteroid spray treatment, acute uncomplicated dermatitis surfaces corticosteroid therapy) in the past 6 months Any prior administration of blood products in last 3 months Any prior administration of any attenuated live vaccine in last 14 days Any prior administration of subunit or inactivated vaccines in last 7 days Any acute infection or serious infection needing systemic antibiotics or antiviral treatment in last 7 days Any fever with temperature &gt;=38.0°C on axillary setting in last 3 days Any other factors judged by investigator, that may interfere subject's compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pneumococcal conjugate vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
</DOC>